Welcome to our dedicated page for Medtronic SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medtronic plc filings document material events, capital structure, registered securities, governance matters, and operating and financial disclosures for a medical-device company organized in Ireland. The 8-K record identifies MDT ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, alongside current reports used for company events and financial-result communications.
The filing record also includes exchange and registration status for debt securities, including a Form 25 notice tied to removal from listing and registration of a guarantor class of senior notes. These disclosures frame Medtronic's public-company obligations around equity, debt instruments, material agreements, and regulatory or clinical developments.
Medtronic filed its FY2025 10-K report, detailing operations across four major segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. The company maintains a strong international presence with significant operations in both US and international markets.
Key operational highlights include:
- Strategic focus on enterprise excellence and simplification restructuring programs
- Continued investment in research and development across all segments
- Notable divestiture of the Ventilator Product Line in February 2024
- Completion of the Renal Care Solutions/Mozarc transaction in April 2023
Financial structure includes various senior notes due between 2025-2053 with interest rates ranging from 0% to 4.15%. The company maintains a diversified debt portfolio in multiple currencies (USD, EUR, JPY). Significant emphasis on fair value measurements and risk management, particularly in Level 3 assets including revenue and product development milestones.